Pluri Inc. (PLUR)
NASDAQ: PLUR · Real-Time Price · USD
4.080
-0.220 (-5.12%)
Oct 8, 2025, 4:00 PM EDT - Market closed

Company Description

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries.

It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform.

The company’s product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform.

It also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products.

The company operates in the field of regenerative medicine, food tech, immunotherapy, CDMO, and AgTech.

It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors.

The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022.

Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Pluri Inc.
Pluri logo
CountryIsrael
Founded2001
IndustryBiotechnology
SectorHealthcare
Employees142
CEOYaacov Yanay

Contact Details

Address:
MATAM Advanced Technology Park, Building No. 5
Haifa, 3508409
Israel
Phone972 74 710 8600
Websitepluri-biotech.com

Stock Details

Ticker SymbolPLUR
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJuly - June
Reporting CurrencyUSD
CIK Code0001158780
CUSIP Number72942G104
ISIN NumberUS72942G2030
Employer ID98-0351734
SIC Code2836

Key Executives

NamePosition
Yaacov YanayPresident, Chief Executive Officer and Director
Liat ZaltsChief Financial Officer and Treasurer
Lior RavivChief Technology Officer
Dr. Arthur Machlenkin Ph.D.Chief Scientific Officer
Hagit GalGeneral Counsel
Nofar Glaich-DabachVice President of Human Resources
Orly AmiranChief Quality Officer
Efrat KaduriChief Business Development Officer of Pharma
Nimrod Bar ZviChief Commercial Officer

Latest SEC Filings

DateTypeTitle
Sep 25, 2025EFFECTNotice of Effectiveness
Sep 17, 2025S-3Registration statement under Securities Act of 1933
Sep 17, 2025S-8Securities to be offered to employees in employee benefit plans
Sep 17, 2025S-8Securities to be offered to employees in employee benefit plans
Sep 17, 202510-KAnnual Report
Sep 12, 20258-KCurrent Report
Sep 11, 20258-KCurrent Report
Jul 3, 20258-KCurrent Report
Jun 9, 2025SCHEDULE 13D/AFiling
May 28, 2025UPLOADFiling